CL2007003879A1 - Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson. - Google Patents

Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson.

Info

Publication number: CL2007003879A1
Authority: CL; Chile
Prior art keywords: carboxamida; aril; epilepsy; parkinson; alzheimer
Prior art date: 2006-12-29

Application number

CL200703879A

Other languages

English (en)

Inventor

Andreas Kling

Wilfried Hornberger

Original Assignee

Basf Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-29

Filing date

2007-12-28

Publication date

2008-07-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39226751&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007003879(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-12-28 Application filed by Basf Ag filed Critical Basf Ag

2008-07-04 Publication of CL2007003879A1 publication Critical patent/CL2007003879A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL200703879A 2006-12-29 2007-12-28 Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson. CL2007003879A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP06127369		2006-12-29

Publications (1)

Publication Number	Publication Date
CL2007003879A1 true CL2007003879A1 (es)	2008-07-04

Family

ID=39226751

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200703879A CL2007003879A1 (es)	2006-12-29	2007-12-28	Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson.

Country Status (28)

Country	Link
US (4)	US8436034B2 (es)
EP (2)	EP2439205B1 (es)
JP (1)	JP5295976B2 (es)
KR (3)	KR101578674B1 (es)
CN (1)	CN101616908B (es)
AR (2)	AR064693A1 (es)
AT (1)	ATE544758T1 (es)
AU (1)	AU2007341232B2 (es)
BR (1)	BRPI0721298A2 (es)
CA (1)	CA2673580C (es)
CL (1)	CL2007003879A1 (es)
CO (1)	CO6190617A2 (es)
DK (1)	DK2439205T3 (es)
EC (1)	ECSP099476A (es)
ES (2)	ES2536626T3 (es)
GT (1)	GT200900186A (es)
IL (2)	IL199447A (es)
MX (1)	MX2009007050A (es)
MY (1)	MY147780A (es)
NZ (2)	NZ599860A (es)
PE (1)	PE20081609A1 (es)
PL (1)	PL2439205T3 (es)
PT (1)	PT2439205E (es)
RU (2)	RU2485114C2 (es)
TW (1)	TWI405571B (es)
UA (1)	UA100501C2 (es)
UY (1)	UY30850A1 (es)
WO (1)	WO2008080969A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101616908B (zh)	2006-12-29	2014-09-10	Abbvie德国有限责任两合公司	羧酰胺化合物及它们作为钙蛋白酶抑制剂的用途
TWI453019B (zh) *	2007-12-28	2014-09-21	Abbvie Deutschland	甲醯胺化合物
CN102186809A (zh) *	2008-08-14	2011-09-14	拜尔农作物科学股份公司	杀虫性的4-苯基-1h-吡唑
TWI519530B (zh) *	2009-02-20	2016-02-01	艾伯維德國有限及兩合公司	羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途
US8236798B2 (en) *	2009-05-07	2012-08-07	Abbott Gmbh & Co. Kg	Carboxamide compounds and their use as calpain inhibitors
ES2444779T3 (es) *	2009-09-28	2014-02-26	F. Hoffmann-La Roche Ag	Compuestos de benzoxazepina inhibidores de la PI3K y su utilización en el tratamiento de cáncer
US8598211B2 (en)	2009-12-22	2013-12-03	Abbvie Inc.	Carboxamide compounds and their use as calpain inhibitors IV
US9051304B2 (en)	2009-12-22	2015-06-09	AbbVie Deutschland GmbH & Co. KG	Carboxamide compounds and their use as calpain inhibitors V
EP2563446A1 (en)	2010-04-30	2013-03-06	Abbott Cardiovascular Systems Inc.	Improved balloon catheter exhibiting rapid inflation and deflation
EP2648731B1 (en)	2010-12-09	2017-01-25	Abbvie Deutschland GmbH & Co. KG	Carboxamide compounds and their use as calpain inhibitors v
US8669370B2 (en)	2011-01-26	2014-03-11	Sanofi	Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
WO2013126283A1 (en)	2012-02-20	2013-08-29	E. I. Du Pont De Nemours And Company	Fungicidal pyrazoles
CA2867210A1 (en) *	2012-04-03	2013-10-10	AbbVie Deutschland GmbH & Co. KG	Carboxamide compounds and their use as calpain inhibitors v
CN105492433B (zh)	2013-03-29	2018-11-23	武田药品工业株式会社	6-(5-羟基-1h-吡唑-1-基)烟碱酰胺衍生物和其作为phd抑制剂的用途
HUE14755117T2 (hu) *	2013-08-14	2018-12-28	Kalvista Pharmaceuticals Ltd	Plazma-kallikrein inhibitorok
TWI636047B (zh)	2013-08-14	2018-09-21	英商卡爾維斯塔製藥有限公司	雜環衍生物
GB201421083D0 (en)	2014-11-27	2015-01-14	Kalvista Pharmaceuticals Ltd	Enzyme inhibitors
GB201421085D0 (en)	2014-11-27	2015-01-14	Kalvista Pharmaceuticals Ltd	New enzyme inhibitors
MX2018007527A (es)	2015-12-22	2018-09-07	Syngenta Participations Ag	Derivados de pirazol activos como pesticidas.
CN107857723A (zh) *	2016-01-26	2018-03-30	绍兴瑞康生物科技有限公司	一种羧酰胺类化合物及其制备方法和应用
EP3426674A4 (en)	2016-03-09	2019-08-14	Blade Therapeutics, Inc.	CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
HRP20201131T1 (hr)	2016-05-31	2020-10-30	Kalvista Pharmaceuticals Limited	Derivati pirazola kao inhibitori kalikreina plazme
GB201609603D0 (en)	2016-06-01	2016-07-13	Kalvista Pharmaceuticals Ltd	Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en)	2016-06-01	2016-07-13	Kalvista Pharmaceuticals Ltd	Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
US11292801B2 (en)	2016-07-05	2022-04-05	Blade Therapeutics, Inc.	Calpain modulators and therapeutic uses thereof
AU2017336523B2 (en)	2016-09-28	2022-07-21	Blade Therapeutics, Inc.	Calpain modulators and therapeutic uses thereof
AU2018317805B2 (en) *	2017-08-16	2021-04-15	BioVersys AG	Novel compounds
GB201719881D0 (en)	2017-11-29	2018-01-10	Kalvista Pharmaceuticals Ltd	Solid forms of plasma kallikrein inhibitor and salts thereof
DK3716952T3 (da)	2017-11-29	2022-03-14	Kalvista Pharmaceuticals Ltd	Doseringsformer omfattende en plasmakallikrein-inhibitor
KR20200139702A (ko) *	2018-03-28	2020-12-14	블레이드 테라퓨틱스, 인크.	칼페인 조정자 및 그 치료학적 용도
US11034669B2 (en)	2018-11-30	2021-06-15	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
WO2021028645A1 (en)	2019-08-09	2021-02-18	Kalvista Pharmaceuticals Limited	Plasma kallikrein inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH21213A (en)	1984-10-26	1987-08-21	Fujisawa Pharmaceutical Co	Benzene- and pyrazole- fused heterocyclic compound and pharmaceutical composition comprising the same
US4826835A (en)	1985-10-23	1989-05-02	Rorer Pharmaceutical Corporation	Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
US4743608A (en)	1986-07-15	1988-05-10	Rorer Pharmaceutical Corporation	Pyridone-pyridyl-imidazolyl and triazolyl compounds and their use as cardiotonic agents
US4888352A (en)	1989-03-22	1989-12-19	Sterling Drug Inc.	3,4, or 5-aryl-1H-pyrazole-1-alkanamides as antiarrhythmic agents, compositions and use
GB9412603D0 (en) *	1994-06-23	1994-08-10	Sandoz Ltd	Organic compounds
DE19642591A1 (de)	1996-10-15	1998-04-16	Basf Ag	Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
DE19650975A1 (de)	1996-12-09	1998-06-10	Basf Ag	Neue heterocyclisch substituierte Benzamide und deren Anwendung
PL334059A1 (en)	1996-12-11	2000-01-31	Basf Ag	Ketone benzamides useful as calpain inhibitors
US6127556A (en)	1996-12-31	2000-10-03	G. D. Searle & Co.	Epoxide formation by continuous in-situ synthesis process
US6083944A (en) *	1997-10-07	2000-07-04	Cephalon, Inc.	Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
ES2325140T3 (es) *	1998-04-20	2009-08-26	ABBOTT GMBH & CO. KG	Amidas sustituidas con heterociclos como inhibidores de la calpaina.
CA2328396C (en)	1998-04-20	2009-02-10	Basf Aktiengesellschaft	New substituted amides, their production and their use
BR9909819A (pt)	1998-04-20	2000-12-19	Basf Ag	Amida, uso de amidas, e, preparação farmacêutica para uso oral, parenteral ou intraperitoneal
DE19817461A1 (de)	1998-04-20	1999-10-21	Basf Ag	Neue substituierte Benzamide, deren Herstellung und Anwendung
DE19818614A1 (de)	1998-04-20	1999-10-21	Basf Ag	Neue substituierte Amide, deren Herstellung und Anwendung
DE19817459A1 (de) *	1998-04-20	1999-10-21	Basf Ag	Neue heterozyklische substituierte Amide, Herstellung und Anwendung
WO1999061423A1 (de) *	1998-05-25	1999-12-02	Basf Aktiengesellschaft	Neue heterocyclische substituierte amide, deren herstellung und anwendung
AR018915A1 (es) *	1998-06-24	2001-12-12	Smithkline Beecham Corp	Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos
AU2001245764A1 (en) *	2000-03-15	2001-09-24	Axys Pharmaceuticals, Inc.	Novel compounds and compositions as protease inhibitors
JP2001261675A (ja)	2000-03-21	2001-09-26	Mitsui Chemicals Inc	ピラゾリン誘導体またはテトラヒドロピリダジン誘導体を含有する医薬
US6995162B2 (en) *	2001-01-12	2006-02-07	Amgen Inc.	Substituted alkylamine derivatives and methods of use
DE10114762A1 (de)	2001-03-26	2002-10-02	Knoll Gmbh	Verwendung von Cysteinprotease-Inhibitoren
WO2003075836A2 (en) *	2002-03-05	2003-09-18	Merck Frosst Canada & Co.	Cathepsin cysteine protease inhibitors
EP1610263A1 (en)	2004-06-18	2005-12-28	Sicpa Holding S.A.	Item carrying at least two data storage elements
WO2006080439A1 (ja)	2005-01-28	2006-08-03	Taisho Pharmaceutical Co., Ltd.	三環性化合物
CN101616908B (zh) *	2006-12-29	2014-09-10	Abbvie德国有限责任两合公司	羧酰胺化合物及它们作为钙蛋白酶抑制剂的用途
TWI453019B (zh) *	2007-12-28	2014-09-21	Abbvie Deutschland	甲醯胺化合物

2007
- 2007-12-28 CN CN200780051850.2A patent/CN101616908B/zh not_active Expired - Fee Related
- 2007-12-28 DK DK11195099.4T patent/DK2439205T3/da active
- 2007-12-28 UY UY30850A patent/UY30850A1/es not_active Application Discontinuation
- 2007-12-28 AR ARP070105965A patent/AR064693A1/es unknown
- 2007-12-28 TW TW096150930A patent/TWI405571B/zh not_active IP Right Cessation
- 2007-12-28 EP EP11195099.4A patent/EP2439205B1/en not_active Not-in-force
- 2007-12-28 AT AT07866322T patent/ATE544758T1/de active
- 2007-12-28 CA CA2673580A patent/CA2673580C/en not_active Expired - Fee Related
- 2007-12-28 NZ NZ599860A patent/NZ599860A/xx not_active IP Right Cessation
- 2007-12-28 US US11/990,652 patent/US8436034B2/en not_active Expired - Fee Related
- 2007-12-28 BR BRPI0721298-4A patent/BRPI0721298A2/pt not_active IP Right Cessation
- 2007-12-28 KR KR1020097016007A patent/KR101578674B1/ko not_active Expired - Fee Related
- 2007-12-28 WO PCT/EP2007/064617 patent/WO2008080969A1/en not_active Ceased
- 2007-12-28 MX MX2009007050A patent/MX2009007050A/es active IP Right Grant
- 2007-12-28 RU RU2009129119/04A patent/RU2485114C2/ru not_active IP Right Cessation
- 2007-12-28 NZ NZ577719A patent/NZ577719A/en not_active IP Right Cessation
- 2007-12-28 ES ES11195099.4T patent/ES2536626T3/es active Active
- 2007-12-28 ES ES07866322T patent/ES2381879T3/es active Active
- 2007-12-28 MY MYPI20092635A patent/MY147780A/en unknown
- 2007-12-28 PL PL11195099T patent/PL2439205T3/pl unknown
- 2007-12-28 PT PT111950994T patent/PT2439205E/pt unknown
- 2007-12-28 AU AU2007341232A patent/AU2007341232B2/en not_active Ceased
- 2007-12-28 KR KR1020157020180A patent/KR20150090281A/ko not_active Withdrawn
- 2007-12-28 JP JP2009543479A patent/JP5295976B2/ja not_active Expired - Fee Related
- 2007-12-28 CL CL200703879A patent/CL2007003879A1/es unknown
- 2007-12-28 UA UAA200907938A patent/UA100501C2/uk unknown
- 2007-12-28 KR KR1020157020182A patent/KR20150090282A/ko not_active Ceased
- 2007-12-28 EP EP07866322A patent/EP2121653B1/en active Active
2008
- 2008-01-02 PE PE2008000057A patent/PE20081609A1/es not_active Application Discontinuation
- 2008-02-22 US US12/070,941 patent/US7728012B2/en not_active Expired - Fee Related
- 2008-02-22 US US12/072,065 patent/US7799809B2/en not_active Expired - Fee Related
2009
- 2009-06-18 IL IL199447A patent/IL199447A/en not_active IP Right Cessation
- 2009-06-26 CO CO09066778A patent/CO6190617A2/es active IP Right Grant
- 2009-06-29 EC EC2009009476A patent/ECSP099476A/es unknown
- 2009-06-29 GT GT200900186A patent/GT200900186A/es unknown
2010
- 2010-07-15 AR ARP100102569A patent/AR077477A2/es unknown
2013
- 2013-02-01 RU RU2013104459/04A patent/RU2013104459A/ru not_active Application Discontinuation
- 2013-03-25 US US13/849,826 patent/US9139557B2/en not_active Expired - Fee Related
2014
- 2014-03-11 IL IL231463A patent/IL231463A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR20150090281A (ko)	2015-08-05
EP2439205A1 (en)	2012-04-11
TWI405571B (zh)	2013-08-21
IL199447A (en)	2014-04-30
RU2485114C2 (ru)	2013-06-20
JP2010514738A (ja)	2010-05-06
GT200900186A (es)	2012-03-16
US9139557B2 (en)	2015-09-22
TW200845979A (en)	2008-12-01
US20080234330A1 (en)	2008-09-25
AU2007341232A1 (en)	2008-07-10
CA2673580A1 (en)	2008-07-10
PL2439205T3 (pl)	2015-08-31
AR077477A2 (es)	2011-08-31
IL231463A (en)	2016-02-29
US20130245003A1 (en)	2013-09-19
WO2008080969A1 (en)	2008-07-10
UY30850A1 (es)	2008-07-31
ES2536626T3 (es)	2015-05-27
PT2439205E (pt)	2015-07-16
JP5295976B2 (ja)	2013-09-18
US7728012B2 (en)	2010-06-01
BRPI0721298A2 (pt)	2014-03-25
KR101578674B1 (ko)	2015-12-18
PE20081609A1 (es)	2008-11-12
MX2009007050A (es)	2009-09-23
MY147780A (en)	2013-01-31
CA2673580C (en)	2015-11-24
RU2013104459A (ru)	2014-08-10
HK1138833A1 (en)	2010-09-03
EP2121653B1 (en)	2012-02-08
EP2439205B1 (en)	2015-03-11
RU2009129119A (ru)	2011-02-10
KR20150090282A (ko)	2015-08-05
DK2439205T3 (da)	2015-06-22
CO6190617A2 (es)	2010-08-19
ES2381879T3 (es)	2012-06-01
IL231463A0 (en)	2014-04-30
EP2121653A1 (en)	2009-11-25
ECSP099476A (es)	2009-07-31
US20080234329A1 (en)	2008-09-25
NZ599860A (en)	2013-09-27
UA100501C2 (uk)	2013-01-10
KR20090097205A (ko)	2009-09-15
AR064693A1 (es)	2009-04-22
CN101616908A (zh)	2009-12-30
AU2007341232B2 (en)	2013-01-31
NZ577719A (en)	2012-06-29
CN101616908B (zh)	2014-09-10
ATE544758T1 (de)	2012-02-15
US7799809B2 (en)	2010-09-21
US8436034B2 (en)	2013-05-07
US20100298326A1 (en)	2010-11-25

Publication	Publication Date	Title
CL2007003879A1 (es)	2008-07-04	Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson.
CL2007001042A1 (es)	2008-02-08	Compuestos derivados de tioxantina; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de desordenes neuroinflamatorios como esclerosis multiple, parkinson, en desordenes ateroscleroticos, cardio- y cerebrovascular, des
CL2007003774A1 (es)	2008-04-18	Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
CL2008000531A1 (es)	2008-09-22	Compuestos derivados de heterociclos, inhibidores de la aspartilproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades cardiovasculares, cognitivas y neurodegenerativas tales como la enfermeda
CL2008001994A1 (es)	2008-09-22	Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CL2008000434A1 (es)	2008-08-22	Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
CL2008000690A1 (es)	2008-09-12	Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
CL2007002996A1 (es)	2008-06-13	Compuestos derivados de quinolina sustituido, moduladores de los receptores x del higado; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome coronario agudo, alzheimer, diabetes y aterosclerosis.
CL2008001125A1 (es)	2008-10-24	Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
CL2009000990A1 (es)	2010-10-15	Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras.
CL2007000806A1 (es)	2008-05-30	Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008001126A1 (es)	2008-10-24	Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
CL2007002593A1 (es)	2008-06-13	Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
CL2007000161A1 (es)	2008-05-30	Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2008001025A1 (es)	2008-10-17	Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer.
CL2007002974A1 (es)	2008-05-23	Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
CL2008001076A1 (es)	2008-10-24	Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008000791A1 (es)	2008-05-30	Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
CL2008001921A1 (es)	2008-10-17	Compuestos derivados de heterociclos sustituidos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ictus, isquemia cerebral, alzheimer, dolor, entre otras.
CL2008000307A1 (es)	2008-05-30	Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc.
CL2008000875A1 (es)	2008-10-03	Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras.
CL2008000348A1 (es)	2008-08-18	Compuestos derivados de carboxamida, inhibidores de la actividad de la proteina quinasa b; composicion farmaceutica; proceso para prepararla; y uso en el tratamiento de enfermedades tales como cancer y artritis.
CL2007002610A1 (es)	2008-02-01	Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2013001654A1 (es)	2014-03-28	Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2007002513A1 (es)	2008-04-04	Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.